Trigeminal neuralgia is a peripheral neuropathy with clinical manifestations of transient recurrent severe pain in the distribution area of the facial trigeminal nerve, whose treatment includes pharmacotherapy, closed therapy and surgery, etc. Among them, pharmacotherapy is preferred, and other therapies are chosen when they are ineffective or fail. The first choice of drug for trigeminal neuralgia is carbamazepine, starting from a small dose and trying to maintain with the lowest effective dose, which is contraindicated for pregnant women. Common adverse effects such as dizziness, drowsiness, dry mouth, nausea, indigestion, unstable walking, etc. Occasionally, rash, leukopenia, ataxia, diplopia, hepatic impairment, etc. need to stop the drug. In addition, oxcarbazepine has the same efficacy as carbamazepine. Phenytoin sodium can be given intravenously to terminate acute attacks and is effective in combination with carbamazepine when necessary. Lamotrigine, baclofen and other drugs can be tried in refractory cases. For those who refuse surgical treatment or are not suitable for surgical treatment, anhydrous alcohol or glycerin can be used to close the trigeminal nerve branches or the semilunar ganglion to destroy the sensory nerve cells, which can achieve the effect of pain relief. The adverse effect is the loss of facial sensation in the injection area. Surgical treatment includes trigeminal nerve sensory root partial excision or Gamma knife treatment, which can provide precise pain relief. In recent years, trigeminal nerve decompression with microvascular decompression has been used to achieve pain relief without cutting the nerve. In summary, trigeminal neuralgia can be treated by drugs, local closure and surgery. Patients can choose the appropriate method for treatment under the guidance of a neurologist.